Literature DB >> 35978180

Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia.

Marta Santaliestra1, Francisca Ferrer-Marín2, Alberto Alvarez-Larrán3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35978180     DOI： 10.1007/s00277-022-04956-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  2 in total

1.  A long-term study of young patients with essential thrombocythemia treated with anagrelide.

Authors:  Maria Gabriella Mazzucconi; Roberta Redi; Sayla Bernasconi; Luisa Bizzoni; Francesco Dragoni; Roberto Latagliata; Cristina Santoro; Franco Mandelli
Journal:  Haematologica       Date:  2004-11       Impact factor: 9.941

Review 2.  How to Treat Essential Thrombocythemia and Polycythemia Vera.

Authors:  Carlos Besses; Alberto Alvarez-Larrán
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.